Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | ABT-165 |
Trade Name | |
Synonyms | Dilpacimab|ABT 165|ABT165 |
Drug Descriptions |
Dilpacimab (ABT-165) is a bispecific antibody that binds to and inhibits signaling of both DLL4 and VEGF, which potentially results in tumor growth inhibition (PMID: 29592882). |
DrugClasses | DLL4 Antibody 7 VEGF Antibody 11 |
CAS Registry Number | 1791420-09-1 |
NCIT ID | C116750 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ABT-165 | ABT-165 | 0 | 1 |
ABT-165 + Budigalimab | ABT-165 Budigalimab | 0 | 1 |
ABT-165 + Budigalimab + Paclitaxel | ABT-165 Budigalimab Paclitaxel | 0 | 1 |
ABT-165 + Fluorouracil + Irinotecan + Leucovorin | ABT-165 Fluorouracil Irinotecan Leucovorin | 0 | 2 |
ABT-165 + Paclitaxel | ABT-165 Paclitaxel | 0 | 1 |